Seagen Reports First Quarter 2022 Financial Results

28.04.2022 - Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV (enfortumab vedotin-ejfv), TUKYSA (tucatinib), ADCETRIS (brentuximab vedotin) and TIVDAK (tisotumab ...

Related Keywords

United Kingdom ,United States ,Norway ,Iceland ,Japan ,California ,Liechtenstein ,Canada ,Russia ,Washington ,Switzerland ,Seattle ,Ukraine ,Great Britain ,American ,Disitamab Vedotin ,Daiichi Sankyo ,Roche Polivy ,Glaxosmithkline ,National Cancer Institute ,American Society Of Clinical Oncology ,Genentech ,European Commission Ec Approval ,Patent Infringement Case Against Daiichi Sankyo Co ,Trademark Office ,Company Annual Report On Form ,European Union ,European Union Member States ,Committee For Medicinal Products Human Use ,National Institutes Of Health ,Children Oncology Group ,Seagen Inc ,Exchange Commission ,Development Rd Expenses ,American Association For Cancer Research ,Roche Group ,European Commission ,Previously Treated Metastatic Urothelial Cancer ,Initial Results ,Muscle Invasive Bladder Cancer ,American Society ,Clinical Oncology Genitourinary Cancers Symposium ,Preclinical Data ,Non Muscle Invasive Bladder Cancer ,American Association ,Cancer Research ,Annual Meeting ,Report Top Line Results ,First Line Metastatic Urothelial Cancer ,First Patient ,First Line Metastatic ,Positive Colorectal Cancer ,Significantly Improves Overall Survival ,Newly Diagnosed Patients ,Advanced Hodgkin Lymphoma ,Clinical Oncology ,Biologics License Application ,Oncology Group ,Oral Presentation ,National Institutes ,Solid Tumor Basket Trial ,Multidisciplinary Head ,Neck Cancers ,Pivotal Trial ,Two Novel Antibody Drug Conjugates ,Jury Award ,Patent Infringement Case Against Daiichi Sankyo ,Patent Trial ,Appeal Board ,Commercialize Multiple Novel ,Medicinal Products ,Human Use ,License Agreement ,Product Sales ,License Agreement Revenues ,Annual Report ,Consolidated Statements ,Months Ended March ,Seagen ,